• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硼诺司他:具有定制选择性的碳硼烷封端组蛋白去乙酰化酶抑制剂的固相合成

Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile.

作者信息

Selg Christoph, Schöler Andrea, Schliehe-Diecks Julian, Hanl Maria, Sinatra Laura, Borkhardt Arndt, Sárosi Menyhárt B, Bhatia Sanil, Hey-Hawkins Evamarie, Hansen Finn K

机构信息

Institute for Drug Discovery, Medical Faculty, Leipzig University Brüderstraße 34 04103 Leipzig Germany.

Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine University Düsseldorf Düsseldorf Germany.

出版信息

Chem Sci. 2021 Aug 4;12(35):11873-11881. doi: 10.1039/d1sc02268g. eCollection 2021 Sep 15.

DOI:10.1039/d1sc02268g
PMID:34659728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8442681/
Abstract

The elevated expression of histone deacetylases (HDACs) in various tumor types renders their inhibition an attractive strategy for epigenetic therapeutics. One key issue in the development of improved HDAC inhibitors (HDACis) is the selectivity for single HDAC isoforms over unspecific pan inhibition to minimize off-target toxicity. Utilizing the carborane moiety as a fine-tuning pharmacophore, we herein present a robust solid phase synthetic approach towards tailor-made HDACis meeting both ends of the selectivity spectrum, namely pan inhibition and highly selective HDAC6 inhibition.

摘要

组蛋白脱乙酰酶(HDACs)在多种肿瘤类型中表达上调,这使得抑制HDACs成为一种有吸引力的表观遗传治疗策略。开发改良型HDAC抑制剂(HDACis)的一个关键问题是对单一HDAC亚型的选择性,而非非特异性的泛抑制,以尽量减少脱靶毒性。利用碳硼烷部分作为微调药效团,我们在此提出一种强大的固相合成方法,用于定制HDACis,以满足选择性谱的两端,即泛抑制和高度选择性的HDAC6抑制。

相似文献

1
Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile.硼诺司他:具有定制选择性的碳硼烷封端组蛋白去乙酰化酶抑制剂的固相合成
Chem Sci. 2021 Aug 4;12(35):11873-11881. doi: 10.1039/d1sc02268g. eCollection 2021 Sep 15.
2
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.小分子组蛋白去乙酰化酶抑制剂的类别和亚型选择性的测定
Biochem J. 2008 Jan 15;409(2):581-9. doi: 10.1042/BJ20070779.
3
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.组蛋白去乙酰化酶 6 抑制剂在淋巴增殖性疾病中的治疗策略。
Int J Mol Sci. 2018 Aug 9;19(8):2337. doi: 10.3390/ijms19082337.
4
Histone deacetylase inhibitors as cancer therapeutics.组蛋白去乙酰化酶抑制剂作为癌症治疗药物。
Ann Transl Med. 2016 Aug;4(15):287. doi: 10.21037/atm.2016.07.22.
5
Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative study.探索选择性组蛋白去乙酰化酶抑制剂的结构要求:一项比较研究。
J Biomol Struct Dyn. 2021 Feb;39(2):502-517. doi: 10.1080/07391102.2019.1711191. Epub 2020 Jan 10.
6
Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties.格罗贝克-布勒克本-比尼亚梅介导的具有抗炎特性的选择性 HDAC6 抑制剂的多组分合成。
Bioorg Chem. 2024 Feb;143:107072. doi: 10.1016/j.bioorg.2023.107072. Epub 2024 Jan 2.
7
Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).新型组蛋白去乙酰化酶6(HDAC6)选择性抑制剂:专利评估(WO2014181137)
Expert Opin Ther Pat. 2017 Mar;27(3):229-236. doi: 10.1080/13543776.2017.1282945. Epub 2017 Jan 31.
8
Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors.计算机驱动的寻找选择性组蛋白去乙酰化酶 1 抑制剂的计算工具的开发。
Molecules. 2020 Apr 22;25(8):1952. doi: 10.3390/molecules25081952.
9
Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.一系列肉桂酰羟肟酸组蛋白去乙酰化酶抑制剂的构效关系和作用机制研究。
Bioorg Med Chem. 2021 Apr 1;35:116085. doi: 10.1016/j.bmc.2021.116085. Epub 2021 Feb 23.
10
Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).I 类组蛋白去乙酰化酶抑制剂:酒精使用障碍(AUD)的潜在新型表观遗传治疗药物。
J Med Chem. 2018 Mar 8;61(5):1745-1766. doi: 10.1021/acs.jmedchem.7b00115. Epub 2017 Aug 22.

引用本文的文献

1
Carborane-Based Analogs of Celecoxib and Flurbiprofen, their COX Inhibition Potential, and COX Selectivity Index.塞来昔布和氟比洛芬的碳硼烷类似物、它们的COX抑制潜力及COX选择性指数
ChemMedChem. 2025 Jun 2;20(11):e202500166. doi: 10.1002/cmdc.202500166. Epub 2025 May 4.
2
Advances in Diclofenac Derivatives: Exploring Carborane-Substituted N-Methyl and Nitrile Analogs for Anticancer Therapy.双氯芬酸衍生物的研究进展:探索用于抗癌治疗的碳硼烷取代的N-甲基和腈类似物
ChemMedChem. 2025 Jun 2;20(11):e202500084. doi: 10.1002/cmdc.202500084. Epub 2025 Apr 14.
3
Re-design and evaluation of diclofenac-based carborane-substituted prodrugs and their anti-cancer potential.

本文引用的文献

1
Preparing (Metalla)carboranes for Nanomedicine.为纳米医学制备(金属)碳硼烷。
ChemMedChem. 2021 May 18;16(10):1533-1565. doi: 10.1002/cmdc.202000983. Epub 2021 Mar 19.
2
HDAC6 in Diseases of Cognition and of Neurons.组蛋白去乙酰化酶 6 在认知和神经元疾病中的作用。
Cells. 2020 Dec 23;10(1):12. doi: 10.3390/cells10010012.
3
Investigation of the in vitro and in vivo efficacy of peptoid-based HDAC inhibitors with dual-stage antiplasmodial activity.基于肽的 HDAC 抑制剂具有双重抗疟活性的体外和体内功效研究。
基于双氯芬酸的碳硼烷取代前药的重新设计与评估及其抗癌潜力
Sci Rep. 2024 Dec 16;14(1):30488. doi: 10.1038/s41598-024-81414-x.
4
Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors.固相平行合成双重组蛋白去乙酰化酶-环氧化酶抑制剂。
Molecules. 2023 Jan 20;28(3):1061. doi: 10.3390/molecules28031061.
5
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia.氟代肽基组蛋白去乙酰化酶(HDAC)抑制剂的开发用于治疗耐药性急性白血病。
J Med Chem. 2022 Nov 24;65(22):15457-15472. doi: 10.1021/acs.jmedchem.2c01418. Epub 2022 Nov 9.
6
Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin-HDAC Inhibitor Hybrids as Multitarget Drugs.双氢青蒿素-组蛋白去乙酰化酶抑制剂杂合物作为多靶点药物的合成、抗疟和抗白血病活性
Pharmaceuticals (Basel). 2022 Mar 9;15(3):333. doi: 10.3390/ph15030333.
7
Carboranes as unique pharmacophores in antitumor medicinal chemistry.碳硼烷作为抗肿瘤药物化学中的独特药效基团。
Mol Ther Oncolytics. 2022 Jan 10;24:400-416. doi: 10.1016/j.omto.2022.01.005. eCollection 2022 Mar 17.
Eur J Med Chem. 2021 Feb 5;211:113065. doi: 10.1016/j.ejmech.2020.113065. Epub 2020 Dec 5.
4
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.多组分合成、结合模式及具有分叉封顶基团的选择性组蛋白去乙酰化酶 6(HDAC6)抑制剂的构效关系。
J Med Chem. 2020 Sep 24;63(18):10339-10351. doi: 10.1021/acs.jmedchem.9b01888. Epub 2020 Sep 1.
5
Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs).羟胺酸固载树脂(HAIRs):双靶标 HDAC 抑制剂和 HDAC 降解剂(PROTACs)的合成。
Angew Chem Int Ed Engl. 2020 Dec 7;59(50):22494-22499. doi: 10.1002/anie.202006725. Epub 2020 Oct 9.
6
Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.羟肟酸衍生物作为 HDAC1、HDAC6 和 HDAC8 的抑制剂,对癌细胞系具有抗增殖活性。
Sci Rep. 2020 Jun 26;10(1):10462. doi: 10.1038/s41598-020-67112-4.
7
Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor.广泛使用的组蛋白去乙酰化酶6抑制剂Tubastatin A的结构与体内表征
ACS Med Chem Lett. 2020 Jan 15;11(5):706-712. doi: 10.1021/acsmedchemlett.9b00560. eCollection 2020 May 14.
8
Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron.含硼的组蛋白去乙酰化酶 2(HDAC2)抑制剂。
Chembiochem. 2020 Oct 1;21(19):2786-2791. doi: 10.1002/cbic.202000131. Epub 2020 Jun 16.
9
SynergyFinder: a web application for analyzing drug combination dose-response matrix data.SynergyFinder:一个用于分析药物组合剂量反应矩阵数据的网络应用程序。
Bioinformatics. 2020 Apr 15;36(8):2645. doi: 10.1093/bioinformatics/btaa102.
10
Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE.组蛋白去乙酰化酶抑制剂伏立诺他(Zolinza)的氟化类似物:手性杂合生物电子等排体BITE的验证
ACS Med Chem Lett. 2019 Jul 19;10(9):1336-1340. doi: 10.1021/acsmedchemlett.9b00287. eCollection 2019 Sep 12.